APRE - CIK 0001781983
The table below shows Aprea Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $1.82M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.48M |
| $1.59M |
| $1.76M |
| $1.61M |
| $1.85M |
| Operating income | -$3.43M | -$3.12M | -$3.39M | -$4.09M | -$4.10M | -$3.85M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$3.29M | -$2.97M | -$3.24M | -$3.93M | -$3.78M | -$3.47M |
| EPS (diluted) | -$0.22 | -$0.47 | -$0.53 | -$0.66 | -$0.64 | -$0.58 |